Suchergebnisse - (Person:"Lu, Xinjie")

PubPharm (101)

21

Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis

enthalten in: Cardiovascular drugs and therapy | 2019

von Thota, L. | Ponnusamy, T. | Lu, X. | +1

22

Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis

enthalten in: Cardiovascular drugs and therapy | 2019

von Thota, L. | Ponnusamy, T. | Lu, X. | +1

23

Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis

enthalten in: Cardiovascular drugs and therapy | 2019

von Thota, L. | Ponnusamy, T. | Lu, X. | +1

24

Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis

enthalten in: Cardiovascular drugs and therapy | 2019

von Thota, L. | Ponnusamy, T. | Lu, X. | +1

25

The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer

enthalten in: Current cancer drug targets | 2019

von Lu, X.

26

Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis

enthalten in: Current drug targets | 2019

von Lu, X.

27

The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer

enthalten in: Current cancer drug targets | 2019

von Lu, X.

28

Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis

enthalten in: Current drug targets | 2019

von Lu, X.

29

Author Correction : Immune regulation by oral tolerance induces alternate activation of macrophages and reduces markers of plaque destabilization in Apobtm2Sgy/Ldlrtm1Her/J mice

enthalten in: Scientific reports | 2018

von Thota, L. | Ponnusamy, T. | Philip, S. | +2

ErratumFor: Sci Rep. 2017 Jun 21;7(1):3997. - PMID 28638138

30

MULTI-EPITOPIC CONSTRUCT

enthalten in: Europäisches Patentamt | 2018

von KAKKAR VIJAY | LU XINJIE